Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.045,73+0,05 %

Gold3.290,95+0,02 %

Öl (Brent)65,64+0,19 %

Dow Jones42.661,55-0,24 %

US Tech 10021.362,78-0,36 %

EUR/USD1,12825-0,03 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Silence Therapeutics Aktie

Aktie

ISIN: GB00B9GTXM62 WKN: A1T9PD SYM: SLNCF Land Flagge GB

Großbritannien

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

1,5900

USD

+63,92 %

+0,6200 USD

Letzter Kurs 15.05.25 Nasdaq OTC

Silence Therapeutics Aktie kaufen

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights 08.05.25 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics Welcomes Tim McInerney to Board of Directors 06.05.25 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference 05.03.25 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update 27.02.25 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 13.02.25 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting 09.12.24 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference 26.11.24 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting 18.11.24 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights 14.11.24 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference 13.11.24 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences 27.08.24 · Business Wire (engl.) · Silence Therapeutics
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights 15.08.24 · Business Wire (engl.) · Silence Therapeutics

1
2

Meistgelesen

30 Tage
12 Monate

Silence Therapeutics Welcomes Tim McInerney to Board of Directors 124 Leser
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights 108 Leser

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in ... 168 Leser
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma ... 140 Leser
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights 136 Leser
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American ... 136 Leser
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart ... 132 Leser
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update 132 Leser
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights 128 Leser
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in ... 124 Leser
Silence Therapeutics Welcomes Tim McInerney to Board of Directors 124 Leser
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ... 112 Leser

	
		OSZAR »